Answers are grounded in this paper and cite their sources.
ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
No takes yet. Share an insight, caveat, or question.
Lo‐Coco et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: